隶属于 Sanofi
相关临床试验
20
9 进行中
药物批准
425
批准总数
监管机构
2
监管机构数
成立时间
N/A
进行中（未招募）
6
30.0%
已完成
9
45.0%
尚未招募
3
15.0%
暂停
1
5.0%
终止
1
5.0%
- Rentschler Biopharma SE has appointed Dr. Torsten Wöhr as Chief Executive Officer, effective August 1, 2026, succeeding interim CEO Prof. Dr. Uwe Buecheler. - Dr. Wöhr brings over 25 years of international CDMO and biotechnology experience, most recently serving as Chief Commercial Officer at Bachem Group. - The appointment marks the next phase of the company's corporate strategy focused on long-term growth and sustainable value creation. - Prof. Dr. Uwe Buecheler will step down as interim CEO and resume his role as Vice Chairman of the Supervisory Board.
- The U.S. Patent and Trademark Office issued mixed decisions on Sarepta Therapeutics' patent challenges against Genzyme, denying institution of three inter partes review proceedings while granting one related to gene therapy analytical methods. - The patent disputes involve analytical ultracentrifugation and liquid chromatography/mass spectrometry methods for characterizing adeno-associated virus particles used in gene therapy products including Elevidys®. - These patent challenges are part of ongoing litigation between the companies, with Sarepta reporting $898.7 million in net revenue from Elevidys® in 2025.
- Compass Therapeutics appointed Arjun Prasad as Chief Commercial Officer and Cynthia Sirard as Chief Medical Officer, both effective January 1, 2026. - Prasad brings extensive commercial experience including over 10 successful oncology launches, notably the blockbuster VORANIGO launch in 2024 and TIBSOVO for biliary tract cancer patients. - Sirard contributes more than two decades of oncology drug development expertise, having guided multiple programs through clinical development, pivotal trials, and regulatory approval. - The appointments strengthen Compass's execution capabilities as the company advances tovecimig and its broader immuno-oncology pipeline toward potential commercialization.
- Formation Bio appointed four senior executives including Louis Brenner, MD as Chief Medical Officer and Daniel Neil, PhD as Chief Technology Officer to strengthen its AI-native pharmaceutical model. - Former Pfizer CFO Frank D'Amelio and ex-Incyte CSO Dashyant Dhanak, PhD joined as Strategic Advisors to guide the company's drug licensing and acquisition decisions. - The leadership expansion supports Formation Bio's plan to grow its pipeline from current assets to 10-15 drug candidates over the next 3-5 years. - The company recently secured a €545M out-licensing deal and added a new autoimmune disease asset to its development portfolio.
- Day One Biopharmaceuticals has appointed Michael Vasconcelles, M.D., as Head of Research and Development, bringing over 25 years of oncology research and development expertise to the company. - Dr. Vasconcelles will oversee the company's research, development, and medical affairs infrastructure while supporting OJEMDA's growth and expanding the pipeline of targeted therapies. - The appointment comes at a pivotal time for Day One as it transitions from focusing primarily on pediatric cancer to developing transformative medicines for patients of all ages with life-threatening diseases. - Dr. Vasconcelles previously served as Executive Vice President at ImmunoGen, where he led the transformation into a global biotech enterprise and optimized ELAHERE's commercialization strategy.
- Pharmaceutical and biotech companies across Europe and North America have made significant board appointments, bringing industry veterans and scientific experts to strengthen their leadership teams. - Notable appointments include former CDC Director Dr. Julie Louise Gerberding joining ARTIDIS and former Roche neuroscience head Dr. Paulo Fontoura taking on dual advisory roles. - Companies ranging from clinical-stage biotechs to established pharmaceutical firms are adding expertise in areas including oncology, neuroscience, infectious diseases, and antimicrobial resistance.
- A pioneering European initiative led by Professor Maurizio Scarpa explores integrating digital health innovations including AI, telemedicine, and connected care technologies into care pathways for Lysosomal Storage Disorders. - The project aims to address significant challenges in LSD care including delayed diagnoses, fragmented care pathways, and limited access to specialist care through digital health transformations. - Digital health technologies offer transformative opportunities to enable earlier intervention, enhance care coordination, and empower patients and healthcare providers with innovative tools. - The initiative emphasizes the need for continued generation of high-quality clinical evidence, health economic impact assessment, and multi-stakeholder engagement to optimize care pathways and clinical outcomes.
- Takeda Pharmaceutical is positioning three upcoming late-stage clinical trial readouts as a strategic "inflection point" to offset revenue losses from Vyvanse's generic competition. - The Japanese pharmaceutical giant is focusing on new product launches and pipeline advancement to maintain growth momentum, with particular emphasis on rare disease and neuroscience therapeutic areas. - Industry analysts view Takeda's pipeline strategy as critical for the company's long-term financial stability, as it navigates the challenging transition period of losing exclusivity for one of its top-selling medications.
• AbbVie has partnered with Galapagos NV in a global alliance worth up to $406 million to discover and develop combination therapies targeting key mutations in cystic fibrosis patients. • The collaboration aims to develop oral drugs addressing F508del and G551D mutations in the CFTR protein, with plans to initiate Phase 1 clinical trials by the end of 2014. • This partnership joins other significant industry efforts to combat cystic fibrosis, including Pfizer's expanded six-year research program with the Cystic Fibrosis Foundation worth up to $58 million.
